Sponsor

Teva Neuroscience, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Teva Neuroscience, Inc. appears in 15 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials15
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

15 shown
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsNCT01167426 · lead sponsor · 2010-07-01
COMPLETED
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's DiseaseNCT01049984 · lead sponsor · 2009-12-01
COMPLETED
Therapy Optimization in Multiple Sclerosis (MS)NCT00819000 · lead sponsor · 2008-12-01
COMPLETED
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's DiseaseNCT00399477 · lead sponsor · 2006-10-01
COMPLETED
A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® AloneNCT00240006 · lead sponsor · 2006-01-01
COMPLETED
A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®NCT00239993 · lead sponsor · 2005-08-01
COMPLETED
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.NCT00220922 · lead sponsor · 2004-08-01
COMPLETED
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® TherapyNCT00238654 · lead sponsor · 2003-05-01
COMPLETED
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With LevodopaNCT00203060 · lead sponsor · 1997-07-01
COMPLETED
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyNCT01497652 · collaborator · 2012-01-01
COMPLETED
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer AcetateNCT01454791 · collaborator · 2011-01-01
COMPLETED
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's PatientsNCT01007630 · collaborator · 2009-11-01
UNKNOWN
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease SubjectsNCT00936676 · collaborator · 2009-07-01
COMPLETED
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple SclerosisNCT00819195 · collaborator · 2008-12-01
COMPLETED
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)NCT00937157 · collaborator · 2007-09-01
COMPLETED

Drugs studied in this sponsor's trials

5 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Teva Neuroscience, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo3
rasagiline3
rasagiline mesylate3
glatiramer acetate2
Copaxone1

Sponsor roles

lead sponsor9
collaborator6
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.